...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Medicine >Integrated Exposure-Based Therapy for Co-Occurring Post Traumatic Stress Disorder (PTSD) and Substance Dependence: Predictors of Change in PTSD Symptom Severity
【24h】

Integrated Exposure-Based Therapy for Co-Occurring Post Traumatic Stress Disorder (PTSD) and Substance Dependence: Predictors of Change in PTSD Symptom Severity

机译：创伤后应激障碍（PTSD）和物质依赖共同发生的基于暴露的综合治疗：PTSD症状严重程度变化的预测因子

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This paper examines factors associated with change in PTSD symptom severity among individuals randomised to receive an integrated exposure-based psychotherapy for PTSD and substance dependence–Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE). Outcomes examined include change in PTSD symptom severity as measured by the Clinician Administered PTSD Scale (CAPS), and the reliability and clinical significance of change in PTSD symptom severity. Factors examined include patient baseline characteristics, treatment characteristics, and events over follow-up. The mean difference in CAPS score was 38.24 (SE 4.81). Approximately half (49.1%) demonstrated a reliable and clinically significant improvement in PTSD symptom severity. No one was classified as having demonstrated clinically significant worsening of symptoms. Three independent predictors of reductions in PTSD symptom severity were identified: baseline PTSD symptom severity (β 0.77, SE 0.23, p = 0.001), number of traumas experienced prior to baseline (β ?0.30, SE 0.15, p = 0.049), and number of sessions attended (β 2.05, SE 0.87, p = 0.024). The present study provides further evidence regarding the safety of the COPE treatment and factors associated with improvement in PTSD symptom severity. The identification of only a small number of predictors of the outcome points to the broad applicability of the COPE treatment to PTSD and substance use disorder (SUD) patients.
机译：本文研究了与随机分组接受综合基于暴露的心理治疗PTSD和药物依赖性的个体中与PTSD症状严重性变化相关的因素-PTSD的同时治疗和使用长时间暴露（COPE）的物质使用障碍。检查的结果包括临床医师管理的PTSD量表（CAPS）所测量的PTSD症状严重程度的变化，以及PTSD症状严重程度变化的可靠性和临床意义。检查的因素包括患者基线特征，治疗特征和随访事件。 CAPS得分的平均差异为38.24（SE 4.81）。大约一半（49.1％）的患者在PTSD症状严重程度方面显示出可靠且临床上的显着改善。没有人被归类为已证明临床症状明显恶化。确定了PTSD症状严重程度降低的三个独立预测因素：基线PTSD症状严重程度（β0.77，SE 0.23，p = 0.001），基线之前经历的创伤次数（β？0.30，SE 0.15，p = 0.049），以及参加的会话数（β2.05，SE 0.87，p = 0.024）。本研究提供了有关COPE治疗的安全性以及与PTSD症状严重程度改善相关的因素的进一步证据。仅确定少数几个预测结果的指标，表明COPE治疗对PTSD和物质使用障碍（SUD）患者的广泛适用性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号